=> d l3
L3 HAS NO ANSWERS
L3 STR



VPA 13-9/10/11 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 11 3
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=> s l3 ful
FULL SEARCH INITIATED 18:05:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 38450 TO ITERATE

100.0% PROCESSED 38450 ITERATIONS 52 ANSWERS
SEARCH TIME: 00.00.03

L4 52 SEA SSS FUL L3

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.82	168.03

FILE 'CAPLUS' ENTERED AT 18:05:22 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 5 Feb 2006 (20060205/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2

L5 2 L2

=> s l4
L6 3 L4

=> s l6 not l5
L7 1 L6 NOT L5

=> d bib abs 1-3 l6

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:638858 CAPLUS
DN 143:153365
TI Preparation of heteroaryl ureas and their use as glucokinase activators
IN Murray, Anthony; Lau, Jesper; Jeppesen, Lone; Vedso, Per; Ankersen, Michael; Lundbeck, Jane Marie; Kristiansen, Marit; Valcarce-Lopez, Maria Carmen; Polisetti, Dharma Rao; Subramanian, Govindan; Andrews, Robert Carl; Christen, Daniel P.; Cooper, Jeremy T.; Santhosh, Kalpathy Chidambareswaran
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 335 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005066145	A1	20050721	WO 2005-DK2	20050106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DK 2004-13	A	20040106	
DK 2004-1272	A	20040823	
DK 2004-1897	A	20041207	

OS MARPAT 143:153365
GI



I



II

AB Title compds. I [wherein R1, R2 = (un)substituted cycloalk(en)yl, heterocyclyl or heterocycloalkenyl; A = (un)substituted heteroaryl, or pharmaceutically acceptable salts, stereoisomers and tautomers thereof] were prepared For example, treatment of 2-aminothiazole with carbonyldiimidazole followed by condensation with dicyclohexylamine gave urea II. The invented compds. are activators of glucokinase, and thus may

be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial (no data).

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:756712 CAPLUS
DN 141:260563
TI Preparation of isoquinolinyl piperidinyl/pyrrolidinyl urea derivatives as vanilloid receptor 1 antagonists for the treatment of pain
IN Moss, Stephen Frederick; Rami, Harshad Kantilal; Thompson, Mervyn; Witty, David Richard
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004078749	A1	20040916	WO 2004-GB978	20040305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1603899	A1	20051214	EP 2004-717691	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRAI GB 2003-5165	A	20030306		
GB 2003-16554	A	20030715		
WO 2004-GB978	W	20040305		

OS MARPAT 141:260563
GI



I



II

AB N-Isoquinolinyl ureas of formula I, wherein P is (un)substituted isoquinolinyl; P' is (un)substituted Ph, pyridinyl, pyrimidinyl or thiazolyl; A is (CH2)r; B is (CH2)s; r is 1-3; s is 0-2; r + s is 2-4; n is 0-3, were prepared as vanilloid receptor 1 antagonists. Compds. I, pharmaceutically acceptable salts and solvates thereof, processes for

their preparation, pharmaceutical compns. comprising them, and their use in the treatment or prophylaxis of disorders, such as pain, in which antagonism of the vanilloid receptor 1 (VR1) is beneficial, are claimed. A number of isoquinolinyl piperidinyl/pyrrolidinyl urea derivs. have been synthesized. Thus, condensation of Ph chloroformate with 5-amino-1-methylisoquinoline followed by the addition of 1-(3-chloro-5-(trifluoromethyl)-2-pyridinyl)-4-piperidinamine (preparation given), gave urea II, which was then converted into its hydrochloride salt. All synthesized title compds. showed VR1 antagonist activity with pKb > 6 in a FLIPR based calcium assay, and those with pKb > 7 including II·HCl, were tested for FCA-induced hyperalgesia in the guinea pig and found active.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:97300 CAPLUS
DN 138:153440
TI Preparation of substituted ureas as neuropeptide Y Y5 receptor antagonists
IN Stamford, Andrew W.; Huang, Ying; Li, Guoqing
PA Schering Corporation, USA
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003009845	A1	20030206	WO 2002-US23552	20020724
	WO 2003009845	C2	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2454830	AA	20030206	CA 2002-2454830	20020724
	US 2003207860	A1	20031106	US 2002-202239	20020724
	US 6667319	B2	20031223		
	EP 1418913	A1	20040519	EP 2002-752562	20020724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1558764	A	20041229	CN 2002-818964	20020724
	JP 2005500338	T2	20050106	JP 2003-515237	20020724
	NZ 530429	A	20050930	NZ 2002-530429	20020724
	US 2004102474	A1	20040527	US 2003-692559	20031024
PRAI	US 2001-308433P	P	20010726		
	US 2002-202239	A3	20020724		
	WO 2002-US23552	W	20020724		

OS MARPAT 138:153440
GI



I



II

AB Substituted ureas [I; wherein X = N, C; Z = (substituted) amino, alkyl; D = H, OH, (substituted) alkyl; E = H, (substituted) alkyl, or D and E together can be independently joined together via an alkylene bridge; Q = H, (substituted) alkyl, or D, X, Q and the carbon to which Q is attached can jointly form a 3 to 7-membered ring; g, j, k, m, n, independently = 0, 1, 2, 3; R1 = 1 to 5 substituents, each independently selected from H, OH, halo, haloalkyl, alkyl, cycloalkyl, CN, etc.; R2, R4, independently = 1 to 6 substituents, each independently selected from H, alkyl, alkoxy, OH, etc.; R3 = H, (substituted) alkyl] were prepared For example, compound (II) was prepared by the claimed methodol. The prepared compds. are potent NPY Y5 receptor antagonists (preferred compds. have range of Ki = 0.2 - 10 nM) and, thus, are useful in the treatment of obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT




```
VAR G1=11/10/8
VAR G2=1/2/3
ENTER (DIS), GRA, NOD, BON OR ?:end
L4   STRUCTURE CREATED

=> s l4
SAMPLE SEARCH INITIATED 17:48:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     2415 TO ITERATE

 82.8% PROCESSED     2000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        45353 TO    51247
PROJECTED ANSWERS:               0 TO        0

L5             0 SEA SSS SAM L4

=> s l4 ful
FULL SEARCH INITIATED 17:48:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    47817 TO ITERATE

100.0% PROCESSED    47817 ITERATIONS                                 78 ANSWERS
SEARCH TIME: 00.00.01

L6            78 SEA SSS FUL L4

=> s l6 not l2
L7           75 L6 NOT L2
```

```
=> analyze l3
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
L10         ANALYZE L3 1 RN :     208 TERMS

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      15.28     186.67

FILE 'REGISTRY' ENTERED AT 17:50:11 ON 06 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     5 FEB 2006  HIGHEST RN 873536-40-4
DICTIONARY FILE UPDATES:    5 FEB 2006  HIGHEST RN 873536-40-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s l10
L11         208 L10

=> d his

     (FILE 'HOME' ENTERED AT 17:44:50 ON 06 FEB 2006)

     FILE 'REGISTRY' ENTERED AT 17:44:57 ON 06 FEB 2006
L1              STRUC
L2            3 S L1

     FILE 'CAPLUS' ENTERED AT 17:47:04 ON 06 FEB 2006
L3            1 S L2

     FILE 'REGISTRY' ENTERED AT 17:47:15 ON 06 FEB 2006
L4              STRUC
```

```
L5              0 S L4
L6             78 S L4 FUL
L7             75 S L6 NOT L2

     FILE 'CAPLUS' ENTERED AT 17:48:58 ON 06 FEB 2006
L8             39 S L7
L9             38 S L8 NOT L3
L10           ANALYZE L3 1 RN :     208 TERMS

     FILE 'REGISTRY' ENTERED AT 17:50:11 ON 06 FEB 2006
L11           208 S L10

=> s l7 not l11
L12           30 L7 NOT L11
```

=> d l1
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 3 8
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:97300 CAPLUS
DN 138:153440
TI Preparation of substituted ureas as neuropeptide Y Y5 receptor antagonists
IN Stamford, Andrew W.; Huang, Ying; Li, Guoqing
PA Schering Corporation, USA
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003009845	A1	20030206	WO 2002-US23552	20020724
	WO 2003009845	C2	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2454830	AA	20030206	CA 2002-2454830	20020724
	US 2003207860	A1	20031106	US 2002-202239	20020724
	US 6667319	B2	20031223		
	EP 1418913	A1	20040519	EP 2002-752562	20020724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1558764	A	20041229	CN 2002-818964	20020724
	JP 2005500338	T2	20050106	JP 2003-515237	20020724
	NZ 530429	A	20050930	NZ 2002-530429	20020724
	US 2004102474	A1	20040527	US 2003-692559	20031024
PRAI	US 2001-308433P	P	20010726		
	US 2002-202239	A3	20020724		
	WO 2002-US23552	W	20020724		

OS MARPAT 138:153440
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
      (FILE 'HOME' ENTERED AT 17:44:50 ON 06 FEB 2006)

      FILE 'REGISTRY' ENTERED AT 17:44:57 ON 06 FEB 2006
L1              STRUC
L2            3 S L1

      FILE 'CAPLUS' ENTERED AT 17:47:04 ON 06 FEB 2006
L3            1 S L2

      FILE 'REGISTRY' ENTERED AT 17:47:15 ON 06 FEB 2006
L4              STRUC
L5            0 S L4
L6           78 S L4 FUL
L7           75 S L6 NOT L2

      FILE 'CAPLUS' ENTERED AT 17:48:58 ON 06 FEB 2006
L8           39 S L7
L9           38 S L8 NOT L3
L10         ANALYZE L3 1 RN :     208 TERMS

      FILE 'REGISTRY' ENTERED AT 17:50:11 ON 06 FEB 2006
L11         208 S L10
L12          30 S L7 NOT L11
L13          24 SEARCH L1 SSS  SUB=L12 FUL
L14          10 S L13 AND PHENYLMETHYL
L15          14 S L13 NOT L14

      FILE 'CAPLUS' ENTERED AT 17:54:59 ON 06 FEB 2006
L16          30 S L15
L17           0 S L16 AND (EAT? OR OBES? )
L18           0 S L16 AND (ANOREX? OR CACH? OR BULLI?)

      FILE 'REGISTRY' ENTERED AT 17:57:37 ON 06 FEB 2006

      FILE 'CAPLUS' ENTERED AT 17:58:19 ON 06 FEB 2006
L19           6 S L14

      FILE 'STNGUIDE' ENTERED AT 17:59:22 ON 06 FEB 2006
```

> s l14
L19 6 L14

=> d bib hitstr 1-6

L19 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:777922 CAPLUS
DN 137:279193
TI Preparation of imidazolylalkyl-aminopiperidines as HIV inhbitors
IN Edlin, Christopher David; Redshaw, Sally; Smith, Ian Edward David; Walter, Daryl Simon
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079186	A2	20021010	WO 2002-EP3193	20020321
	WO 2002079186	A3	20030501		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2441778	AA	20021010	CA 2002-2441778	20020321
	BR 2002008572	A	20040330	BR 2002-8572	20020321
	EP 1417202	A2	20040512	EP 2002-732512	20020321
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1500086	A	20040526	CN 2002-807803	20020321
	JP 2004528318	T2	20040916	JP 2002-577812	20020321
	US 2003069276	A1	20030410	US 2002-104117	20020322
	ZA 2003006890	A	20041203	ZA 2003-6890	20030903
PRAI	GB 2001-8099	A	20010330		
	WO 2002-EP3193	W	20020321		

OS MARPAT 137:279193
IT **466665-61-2P**, 1-Benzyl-3-(1-formylpiperidin-4-yl)-1-[1-[[5-methyl-2-(4-trifluoromethylphenyl)-1H-imidazol-4-yl]methyl]piperidin-4-yl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(HIV inhibitor; preparation of imidazolylalkyl-aminopiperidines as HIV inhbitors)
RN 466665-61-2 CAPLUS
CN Urea, N'-(1-formyl-4-piperidinyl)-N-[1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:261205 CAPLUS
DN 130:267220
TI Practical synthesis of ureas
IN Thavonekham, Bounkham
PA Boehringer Ingelheim (Canada) Ltd., Can.
SO Can. Pat. Appl., 39 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2215585	AA	19980317	CA 1997-2215585	19970916
	CA 2215585	C	20040420		
	US 5925762	A	19990720	US 1997-931006	19970915
PRAI	US 1996-26202P	P	19960917		

OS CASREACT 130:267220; MARPAT 130:267220
IT **175023-49-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(practical synthesis of ureas)
RN 175023-49-1 CAPLUS
CN Urea, N,N'-bis[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:259658 CAPLUS
DN 128:294701
TI Preparation of N-bipiperidinylbenzamides and analogs as cell adhesion inhibitors
IN Pieper, Helmut; Linz, Guenter; Austel, Volkhard; Himmelsbach, Frank; Guth, Brian; Weisenberger, Johannes
PA Dr. Karl Thomae G.m.b.H., Germany
SO Ger. Offen., 40 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19643331	A1	19980423	DE 1996-19643331	19961021
	WO 9817646	A1	19980430	WO 1997-EP5683	19971015
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9748674	A1	19980515	AU 1997-48674	19971015
PRAI	DE 1996-19643331	A	19961021		
	WO 1997-EP5683	W	19971015		

OS MARPAT 128:294701

IT 206273-08-7P 206273-33-8P 206273-53-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-bipiperidinylbenzamides and analogs as cell adhesion inhibitors)

RN 206273-08-7 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxylic acid, 4-[[[[1-(2-methoxy-2-oxoethyl)-4-piperidinyl]amino]carbonyl](phenylmethyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 206273-33-8 CAPLUS
CN 1-Piperidineacetic acid, 4-[[[[1,4'-bipiperidin]-4-yl(phenylmethyl)amino]carbonyl]amino]-, methyl ester, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 206273-53-2 CAPLUS
CN 1-Piperidineacetic acid, 4-[[[[1,4'-bipiperidin]-4-yl(phenylmethyl)amino]carbonyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

IT 206274-07-9P 206274-08-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-bipiperidinylbenzamides and analogs as cell adhesion inhibitors)

RN 206274-07-9 CAPLUS
CN 1-Piperidineacetic acid, 4-[[[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl](phenylmethyl)amino]carbonyl]amino]-, methyl ester (9CI) (CA

INDEX NAME)



RN 206274-08-0 CAPLUS
CN 1-Piperidineacetic acid, 4-[[[(phenylmethyl)-4-piperidinylamino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:702201 CAPLUS
DN 128:34510
TI A practical synthesis of ureas from phenyl carbamates
AU Thavonekham, Bounkham
CS Bio-Mega Research Division, Boehringer Ingelheim Ltd., Laval, QC, H7S 2G5, Can.
SO Synthesis (1997), (10), 1189-1194
CODEN: SYNTBF; ISSN: 0039-7881
PB Thieme
DT Journal
LA English
OS CASREACT 128:34510
IT **175023-49-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of ureas from Ph carbamates)
RN 175023-49-1 CAPLUS
CN Urea, N,N'-bis[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:476785 CAPLUS
DN 125:142463
TI Carbodiimide derivatives for use in biotinylations
IN Takenishi, Soichiro; Suzuki, Osamu; Yokomizo, Hirohiko; Ichihara, Tatsuo;

Masuda, Gen; Shiohata, Namiko; Komiya, Kazuko
PA Nisshinbo Industries, Inc., Japan
SO Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 718300	A1	19960626	EP 1995-309433	19951222
EP 718300	B1	20011121		
R: DE, FR, GB				
JP 08176159	A2	19960709	JP 1994-335492	19941222
JP 3583489	B2	20041104		
US 5700935	A	19971223	US 1995-577374	19951222
US 5789588	A	19980804	US 1997-931714	19970916
PRAI JP 1994-335492	A	19941222		
US 1995-577374	A3	19951222		

OS MARPAT 125:142463
IT **179542-50-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carbodiimide derivs. of biotin for use in biotinylations)
RN 179542-50-8 CAPLUS
CN Urea, N-(1-methyl-4-piperidinyl)-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:95731 CAPLUS
DN 124:260782
TI Synthesis of symmetrical and unsymmetrical ureas using unsymmetrical diaryl carbonates
AU Freer, Richard; McKillop, Alexander
CS Synthetic Chem. Dep., SmithKline Beecham Pharmaceuticals, Harlow, CM19 5AW, UK
SO Synthetic Communications (1996), 26(2), 331-49
CODEN: SYNCAV; ISSN: 0039-7911
PB Dekker
DT Journal
LA English
OS CASREACT 124:260782
IT **175023-49-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 175023-49-1 CAPLUS
CN Urea, N,N'-bis[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)